Omaveloxolone ameliorates cognitive dysfunction in APP/PS1 mice by stabilizing the STAT3 pathway

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• Alzheimer's Disease (AD) is a progressive neurodegenerative disorder characterized by amyloid-beta (Aβ) plaque deposition and cognitive decline.
• Identifying effective therapeutic agents and understanding their molecular mechanisms are crucial for combating AD.

Purpose of the Study:

• To evaluate the therapeutic potential of omaveloxolone (RTA408) in a mouse model of Alzheimer's Disease.
• To elucidate the underlying molecular mechanisms of RTA408's efficacy.

Main Methods:

• Network pharmacology was used to assess treatment feasibility.
• Behavioral tests (water maze, Y-maze, open field) evaluated cognitive and emotional status in APP/PS1 mice.
• Immunofluorescence, immunohistochemistry, RNA-seq, and molecular docking identified molecular targets and pathways.
• qRT-PCR, Western blotting, and immunofluorescence validated mechanisms in HT22 and BV2 cell lines.

Main Results:

• RTA408 treatment reduced Aβ plaque deposition and restored hippocampal neurons in APP/PS1 mice, improving cognitive function.
• Therapeutic effects were linked to STAT3 pathway modulation, activating STAT3/OXR1 and NRF2/ARE axes to combat oxidative stress.
• RTA408 inhibited the NFκB/IL6/STAT3 pathway, mitigating microglial activation-induced neuroinflammation.

Conclusions:

• Omaveloxolone (RTA408) demonstrates significant therapeutic potential for Alzheimer's Disease based on preclinical findings.
• The drug effectively targets key pathological hallmarks of AD, including amyloid deposition and neuroinflammation.